CEACAM8 Recombinant Monoclonal Antibody
-
中文名稱：CEACAM8重組抗體
-
貨號：CSB-RA005168MA1HU
-
規(guī)格：￥1320
-
圖片：
-
The Binding Activity of Human CEACAM8 with Anti-CEACAM8 Recombinant Antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Human CEACAM8 (CSB-MP005168HU) at 2 μg/mL can bind Anti-CEACAM8 recombinant antibody, the EC50 is 19.38-21.68 ng/mL.
-
-
其他：
產(chǎn)品詳情
-
產(chǎn)品描述：CSB-RA005168MA1HU 是靶向人源 CEACAM8 蛋白的重組單克隆抗體，采用小鼠雜交瘤技術(shù)制備，具有高親和力與批次穩(wěn)定性。CEACAM8 屬于癌胚抗原相關(guān)細(xì)胞黏附分子家族（CEACAM），主要在中性粒細(xì)胞表面表達，參與炎癥反應(yīng)調(diào)控及病原體識別，其異常表達與慢性炎癥性疾病、感染性疾病及免疫調(diào)節(jié)研究相關(guān)。本抗體經(jīng) ELISA 驗證可特異性識別天然及重組 CEACAM8 蛋白，適用于體外樣本中靶蛋白的定性或半定量檢測。應(yīng)用場景涵蓋炎癥機制研究、免疫細(xì)胞功能分析以及相關(guān)信號通路探索，可為體外細(xì)胞模型、蛋白互作研究或免疫組化實驗提供可靠工具，助力科研人員解析 CEACAM8 在免疫應(yīng)答中的分子作用。
-
Uniprot No.：
-
基因名：
-
別名：Carcinoembryonic antigen CGM6 antibody; Carcinoembryonic antigen gene family member 6 antibody; Carcinoembryonic antigen related cell adhesion molecule 8 antibody; Carcinoembryonic antigen-related cell adhesion molecule 8 antibody; CD 66b antibody; CD 67 antibody; CD66b antibody; CD66b antigen antibody; CD67 antibody; CD67 antigen antibody; CEACAM 8 antibody; CEACAM8 antibody; CEAM8_HUMAN antibody; CGM 6 antibody; CGM6 antibody; NCA 95 antibody; NCA95 antibody; Non-specific cross-reacting antigen NCA-95 antibody; Nonspecific cross reacting antigen NCA 95 antibody; Nonspecific cross reacting antigen NCA95 antibody
-
反應(yīng)種屬：Human
-
免疫原：Recombinant Human CEACAM8 protein
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Non-conjugated
-
克隆類型：Monoclonal
-
抗體亞型：hIgG1
-
純化方式：Affinity-chromatography
-
克隆號：22H9
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：ELISA
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情
-
功能：Cell surface glycoprotein that plays a role in cell adhesion in a calcium-independent manner. Mediates heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Heterophilic interaction with CEACAM8 occurs in activated neutrophils.
-
基因功能參考文獻：
- Increased CD66b positive tumor-infiltrating neutrophils (CD66b + TINs) was significantly associated with presence of metastasis, S stage, and nonseminomatous germ cell tumor diagnosis. PMID: 27863478
- Data suggest ways in which carcinoembryonic antigen-related cell adhesion molecules CEACAM6 and CEACAM8 regulate the biological functions of one another. PMID: 26483485
- Granulocytes from type 2 diabetes patients display higher granulocyte cell surface expression of CD66b compared with values of healthy controls. PMID: 23686079
- The highly elevated gene expression of CEACAM6 and CEACAM8 in primary myelofibrosis can serve as molecular markers of myelofibrotic transformation. PMID: 21470677
- All the leukemic samples showed overexpression of CEACAM6 and 8 when compared with normal granulocytes. PMID: 17909799
- CD66b molecules are involved in regulating adhesion and activation of eosinophils, possibly through their localization in lipid rafts and interaction with other cell surface molecules, such as CD11b. PMID: 18056392
顯示更多
收起更多
-
亞細(xì)胞定位：Cell membrane; Lipid-anchor, GPI-anchor. Cell surface.
-
蛋白家族：Immunoglobulin superfamily, CEA family
-
組織特異性：Expressed in leukocytes of chronic myeloid Leukemia patients and bone marrow.
-
數(shù)據(jù)庫鏈接：
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
